Prostate specific membrane antigen
Prostate-specific membrane antigen (PSMA), encoded by the FOLH1 gene, is a type II transmembrane glycoprotein with enzymatic activity as glutamate carboxypeptidase II (GCPII).
Prostate-specific membrane antigen (PSMA), encoded by the FOLH1 gene, is a type II transmembrane glycoprotein with enzymatic activity as glutamate carboxypeptidase II (GCPII). Although named for its prominent expression in prostate tissue, PSMA is not exclusive to the prostate. It is expressed at lower levels in selected normal tissues, including the nervous system, kidney, and small-intestinal epithelium, and is frequently markedly upregulated in prostate Cancer, particularly in advanced and metastatic disease.
The extracellular domain of PSMA catalyzes the hydrolysis of glutamate-containing substrates, including folate-related compounds and N-acetylaspartylglutamate. Its membrane localization, disease-associated overexpression, and efficient ligand-induced internalization have made PSMA an important biomarker and therapeutic target. PSMA-binding small molecules, antibodies, antibody–drug conjugates, radioligands, and chimeric antigen receptor (CAR) T cells have consequently been investigated for prostate-Cancer imaging and treatment. In targeted radionuclide Therapy, PSMA ligands can deliver beta-emitting radionuclides such as lutetium-177 or alpha-emitting radionuclides such as actinium-225 to PSMA-expressing tumor cells. PSMA expression may also support combination strategies directed at the tumor microenvironment, immune-checkpoint blockade, or additional tumor-associated targets such as integrin αvβ3.
PSMA should be distinguished from prostate-specific antigen (PSA). PSA is a secreted serine protease commonly used as a clinical biomarker, whereas PSMA is a cell-surface enzyme and molecular target. PSMA-directed approaches are therefore intended either to visualize PSMA-positive lesions or to exploit the antigen for selective delivery of Radiation, immune effector activity, or other cytotoxic mechanisms.
- Can early 68Ga-PSMA-11 PET/CT predict 6-month disease control in patients receiving first-line systemic therapy for metastatic clear-cell renal cell carcinoma? Protocol for the multicentre prospective phase II PSMA-RENAL study in Belgium. PMID 42760067
Where the papers sit
9 papers study prostate specific membrane antigen directly. Those 9 are one subject: PSMA-Targeted Cancer Care. PSMA-targeted imaging and therapy span 68Ga- and 18F-labeled PET radiotracers, PET/CT-guided biopsy, radionuclide treatment, and therapeutic nanotechnology. The common aim is to improve tumor detection, disease-control prediction, and selective treatment of prostate cancer. No way of splitting those 9 scores better than chance. 2 new directions follow.
PSMA is used as an inducible synthetic biomarker rather than an endogenous tumor target
Engineered mechanosensitive mesenchymal stem cells in multiple tumor models showed that PSMA expression can be induced locally in response to tumor stiffness, enabling ⁶⁸Ga-PSMA-617 PET detection and ¹⁷⁷Lu-AB-PSMA-617 treatment even when tumors lack endogenous PSMA 42624106Aug. This changes PSMA from a naturally occurring molecular address used for imaging or delivery into a programmable radiotheranostic entry point that can be installed across tumor types.
PSMA is used as a vaccine antigen to generate antitumor immunity
A Nanoplasmid DNA vaccine encoding human PSMA in prophylactic and therapeutic prostate cancer models used PSMA to prime cellular and humoral immunity, prevent metastasis, and enhance PD-1 blockade 42176796May. Rather than serving only as a surface target for externally delivered imaging agents or therapeutics, PSMA becomes the antigen around which an active systemic antitumor immune response is organized.
Recent Findings on Prostate specific membrane antigen
PSMA-Targeted Cancer Care: PSMA-directed imaging and delivery systems are being refined to detect disease, predict treatment control, and concentrate therapy in tumors. Acridine scaffold and ε-benzyl substitution studies improved tumor-to-background contrast, but renal retention remained a pharmacokinetic limitation 42720466Sep42314598Jun. A randomized trial found that [68Ga]Ga-PSMA-11 PET/CT-guided robotic biopsy detected more prostate cancer with fewer complications and less pain than cognitive-fusion biopsy 42315309Jun. The PSMA-RENAL phase II study is testing whether early changes in 68Ga-PSMA-11 PET/CT SUVmax predict Disease Control Rate after immune checkpoint inhibitor-based therapy for metastatic clear-cell renal cell carcinoma 42760067Sep. Preclinical treatments use dual targeting, PSMA-directed nanotherapy, redox-responsive mRNA nanogels, and synthetic PSMA expression to improve radionuclide delivery or therapeutic selectivity, while variable target expression continues to motivate these designs 42503815Jul42442513Jul42372825Jun42624106Aug. A Nanoplasmid PSMA DNA vaccine also enhanced antitumor immunity and response to PD-1 blockade in prostate cancer models, supporting combination strategies alongside imaging and targeted therapy 42176796May.
Written from 9 PubMed abstracts, each one cited by PMID above. Published: 2026-08-20. Last written: 2026-09-20 by GPT. Drafted by language models from published abstracts; not medical advice.